197 related articles for article (PubMed ID: 7511747)
1. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
[TBL] [Abstract][Full Text] [Related]
2. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
[TBL] [Abstract][Full Text] [Related]
4. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
[TBL] [Abstract][Full Text] [Related]
5. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis.
Sudo Y; Kilgore KS; Lucchesi BR
J Cardiovasc Pharmacol; 1995 Aug; 26(2):241-50. PubMed ID: 7475049
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
Mickelson JK; Simpson PJ; Lucchesi BR
J Mol Cell Cardiol; 1989 Apr; 21(4):393-405. PubMed ID: 2746660
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
Gold HK; Coller BS; Yasuda T; Saito T; Fallon JT; Guerrero JL; Leinbach RC; Ziskind AA; Collen D
Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
[TBL] [Abstract][Full Text] [Related]
12. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
[TBL] [Abstract][Full Text] [Related]
16. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery.
Shetler TJ; Bailey BD; Jakubowski JA; Jackson CV
Thromb Res; 1998 Apr; 90(2):95-100. PubMed ID: 9684763
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis.
Shetler TJ; Crowe VG; Bailey BD; Jackson CV
Circulation; 1996 Oct; 94(7):1719-25. PubMed ID: 8840866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
